Replies to post #135446 on Biotech Values

[iwfal]

CLDX -

The Eribulan P3 trial was close in patient pool, and the comparator arm ORR was 5%.

If I remember from looking earlier in the day, the median number of preceding treatments for the Eribulan P3 was 4. For the CDX-011 BC trial it is a remarkable 7. I'd expect that to have a meaningful effect on background rate of ORR. FWIW.